Login to Your Account



'The Trains are on the Track'

New Geron Execs Focused on Finding Clinical Partners

By Tom Wall


Thursday, February 10, 2011
Almost exactly two months after closing a $100 million offering, and with $200 million cash in the bank, Geron Corp. said Wednesday that a new management team is taking over and will look for partners to share the cost of multiple Phase II trials for its telomerase inhibitor product candidate in indications including breast and lung cancers, a Phase II trial of GRN1005 in brain metastases and a pioneering Phase I trial of embryonic stem cell therapy for spinal cord injury.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription